Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Cancers
|
December 24, 2021
Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers
Maria Gracia-Hernandez, Zuleima Munoz, Alejandro Villagra
Frontiers in Pharmacology
|
December 16, 2020
Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019
Maria Gracia-Hernandez, Eduardo M Sotomayor, Alejandro Villagra
Cancer Immunology Research
|
May 19, 2025
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Maria Gracia-Hernandez, Maria Del Mar Maldonado, Jeffrey Schlom, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 28, 2024
Targeting HDAC6 improves anti-CD47 immunotherapy
Maria Gracia-Hernandez, Ashutosh S Yende, Nithya Gajendran, et al.
Molecular Cancer Therapeutics
|
August 16, 2023
Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Satish Kumar R Noonepalle, Scott Grindrod, Nima Aghdam, et al.
Journal for Immunotherapy of Cancer
|
May 13, 2025
Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
Maria Del Mar Maldonado, Maria Gracia-Hernandez, Loc Huu Le, et al.
Cancer Research
|
July 2, 2020
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer
Debarati Banik, Satish Noonepalle, Melissa Hadley, et al.
Scientific Reports
|
October 11, 2019
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Scientific Reports
|
April 18, 2019
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Journal of Medicinal Chemistry
|
August 27, 2025
Improved Pharmacokinetic Profiles of HDAC6 Inhibitors via Cap Group Modifications
Olasunkanmi O Olaoye, Fettah Erdogan, Maria Gracia-Hernandez, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Cancers
|
December 24, 2021
Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers
Maria Gracia-Hernandez, Zuleima Munoz, Alejandro Villagra
Frontiers in Pharmacology
|
December 16, 2020
Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019
Maria Gracia-Hernandez, Eduardo M Sotomayor, Alejandro Villagra
Cancer Immunology Research
|
May 19, 2025
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Maria Gracia-Hernandez, Maria Del Mar Maldonado, Jeffrey Schlom, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 28, 2024
Targeting HDAC6 improves anti-CD47 immunotherapy
Maria Gracia-Hernandez, Ashutosh S Yende, Nithya Gajendran, et al.
Molecular Cancer Therapeutics
|
August 16, 2023
Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Satish Kumar R Noonepalle, Scott Grindrod, Nima Aghdam, et al.
Journal for Immunotherapy of Cancer
|
May 13, 2025
Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
Maria Del Mar Maldonado, Maria Gracia-Hernandez, Loc Huu Le, et al.
Cancer Research
|
July 2, 2020
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer
Debarati Banik, Satish Noonepalle, Melissa Hadley, et al.
Scientific Reports
|
October 11, 2019
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Scientific Reports
|
April 18, 2019
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Journal of Medicinal Chemistry
|
August 27, 2025
Improved Pharmacokinetic Profiles of HDAC6 Inhibitors via Cap Group Modifications
Olasunkanmi O Olaoye, Fettah Erdogan, Maria Gracia-Hernandez, et al.
Page
of 2